Pro-resolving lipid mediators in mycobacterial infection

分枝杆菌感染中的促溶解脂质介质

基本信息

项目摘要

DESCRIPTION (provided by applicant): This proposal examines the role of the pro-resolving lipid mediators, resolvins, protectins, and maresins, in mycobacterial pathogenesis. These recently discovered lipids effectively combat sterile inflammation and promote repair of injured tissue, but their role in inflammation caused by infection remains largely unexplored. Severity of tuberculosis can be increased by two diametrically opposed states: too little inflammation or too much. In both humans and M. marinum-infected zebrafish, a model for tuberculosis, those with high and low activity of leukotriene A4 hydroxylase (LTA4H) had increased infection severity. This was due to excessive production of pro-inflammatory leukotriene B4,causing excess TNF and inflammation in those with the high- LTA4H genotype. In the low-LTA4H genotype, excessive production of anti-inflammatory lipoxin A4 caused inadequate TNF, inhibiting protective inflammation. In Aim 1, this proposal will identify resolvins, protectins, and maresins for the first time in zebrafish using mass spectrometry and determine if these lipids are regulated in response to M. marinum infection. To demonstrate similar functions of these lipids in zebrafish and mammals, their ability to inhibit neutrophil recruitment and TNF production will be assayed. In Aim 2, low- LTA4H and high-LTA4H zebrafish will be generated using morpholino technology and injection of LTA4H transcript. After infection, pro-resolving lipid mediators will be administered to measure the effect of these lipids on hosts of each genotype. If pro-resolving lipid mediators attenuate M. marinum infection in high- LTA4H zebrafish, these lipids have great potential as new treatments for tuberculosis, as a stabilized resolvin analogue is currently in Phase II clinical trials. Completion of these Aims will not only contribute to our understanding of how immunopathology is interwoven with mycobacterial pathogenesis, but also potentially suggest new treatments for diseases with an immunopathology component.
描述(由申请人提供):本提案探讨了促溶解脂质介质,溶解蛋白,保护蛋白和蛋白在分枝杆菌发病机制中的作用。这些最近发现的脂质有效地对抗无菌炎症并促进损伤组织的修复,但它们在感染引起的炎症中的作用仍未得到充分研究。结核病的严重程度可因两种截然相反的状态而增加:炎症过少或过多。在人类和marinum感染的斑马鱼(结核模型)中,白三烯A4羟化酶(LTA4H)活性高和低的斑马鱼感染严重程度增加。这是由于促炎白三烯B4的过量产生,在具有高LTA4H基因型的患者中引起过量的TNF和炎症。在低lta4h基因型中,过量产生抗炎脂素A4导致TNF不足,抑制保护性炎症。在Aim 1中,本提案将首次使用质谱法识别斑马鱼中的溶解蛋白、保护蛋白和蛋白,并确定这些脂质是否在对海洋支原体感染的反应中受到调节。为了证明这些脂质在斑马鱼和哺乳动物中的相似功能,将分析它们抑制中性粒细胞募集和TNF产生的能力。在Aim 2中,将使用morpholino技术和注射LTA4H转录物来产生低LTA4H和高LTA4H的斑马鱼。感染后,将使用促溶解脂质介质来测量这些脂质对每种基因型宿主的影响。如果促溶解脂质介质可以减轻高LTA4H斑马鱼的海洋分枝杆菌感染,那么这些脂质具有很大的潜力,可以作为结核病的新疗法,因为一种稳定的溶解蛋白类似物目前正在II期临床试验中。这些目标的完成不仅有助于我们理解免疫病理与分枝杆菌发病机制的相互作用,而且还可能为具有免疫病理成分的疾病提供新的治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Cressida Arianna Madigan其他文献

Cressida Arianna Madigan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Cressida Arianna Madigan', 18)}}的其他基金

Bacterial disruption of neuroimmune pathways in a transparent brain
透明大脑中神经免疫通路的细菌破坏
  • 批准号:
    10245966
  • 财政年份:
    2021
  • 资助金额:
    $ 4.71万
  • 项目类别:
Pro-resolving lipid mediators in mycobacterial infection
分枝杆菌感染中的促溶解脂质介质
  • 批准号:
    8591975
  • 财政年份:
    2013
  • 资助金额:
    $ 4.71万
  • 项目类别:
Pro-resolving lipid mediators in mycobacterial infection
分枝杆菌感染中的促溶解脂质介质
  • 批准号:
    8702903
  • 财政年份:
    2013
  • 资助金额:
    $ 4.71万
  • 项目类别:

相似国自然基金

软坚散结中药抑制肿瘤相关成纤维细胞研究
  • 批准号:
    81173376
  • 批准年份:
    2011
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目

相似海外基金

Mechanisms of Pro-Resolving Mediators in Periodontal Regeneration
牙周再生中促溶解介质的机制
  • 批准号:
    10764989
  • 财政年份:
    2023
  • 资助金额:
    $ 4.71万
  • 项目类别:
Lipin-1 transcriptional coregulatory activity promotes macrophage pro-resolving response
Lipin-1 转录共调节活性促进巨噬细胞促解析反应
  • 批准号:
    10584961
  • 财政年份:
    2023
  • 资助金额:
    $ 4.71万
  • 项目类别:
Bone Marrow Functions of Novel Pro-Resolving Mediators
新型亲解决介质的骨髓功能
  • 批准号:
    10852343
  • 财政年份:
    2023
  • 资助金额:
    $ 4.71万
  • 项目类别:
Role of Splenic Pro-Resolving Mediators During Exposure to Particulate Air Pollution
暴露于颗粒空气污染期间脾促分解介质的作用
  • 批准号:
    10658099
  • 财政年份:
    2023
  • 资助金额:
    $ 4.71万
  • 项目类别:
Can specialized pro-resolving lipid mediators Resolvin E series be a therapeutic agent for ARDS?
专门的促溶解脂质介质 Resolvin E 系列可以作为 ARDS 的治疗剂吗?
  • 批准号:
    22K08227
  • 财政年份:
    2022
  • 资助金额:
    $ 4.71万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SPMAC: The role of pro-resolving lipid mediators and gut-resident macrophages in regulating early-in-life immune imprinting and adulthood [...]
SPMAC:促溶解脂质介质和肠道驻留巨噬细胞在调节生命早期免疫印记和成年期中的作用[...]
  • 批准号:
    EP/X021122/1
  • 财政年份:
    2022
  • 资助金额:
    $ 4.71万
  • 项目类别:
    Fellowship
Pro-Resolving Inflammatory Mediators in Neurovascular Gains in Aerobic Training (PRIMiNG-AT)
有氧训练中促进神经血管增益的炎症介质 (PRIMiNG-AT)
  • 批准号:
    441673
  • 财政年份:
    2021
  • 资助金额:
    $ 4.71万
  • 项目类别:
    Operating Grants
Diversity Supplement: Novel specialized pro-resolving lipid mediators in resolution of aortic aneurysms and rupture
多样性补充:解决主动脉瘤和破裂的新型专业化脂质介质
  • 批准号:
    10239324
  • 财政年份:
    2021
  • 资助金额:
    $ 4.71万
  • 项目类别:
Aspirin-triggered Specialized Pro-resolving Mediators in Increasing Weight and Atherosclerotic Cardiovascular Disease
阿司匹林触发的专门促缓解介质可增加体重和动脉粥样硬化性心血管疾病
  • 批准号:
    10185076
  • 财政年份:
    2021
  • 资助金额:
    $ 4.71万
  • 项目类别:
Aspirin-triggered Specialized Pro-resolving Mediators in Increasing Weight and Atherosclerotic Cardiovascular Disease
阿司匹林触发的专门促缓解介质可增加体重和动脉粥样硬化性心血管疾病
  • 批准号:
    10591540
  • 财政年份:
    2021
  • 资助金额:
    $ 4.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了